Company intelligence / Profile preview

RiboNova

Wynnewood, Pennsylvania, United States6sense.com ↗

Ownership: Private
Development stage: Other

Overview

RiboNova’s lead program is a Phase 2–ready small molecule drug ("R007", also referred to as probucol) for all forms of genetically confirmed mitochondrial disease. The company has a proprietary platform focused on tRNA-targeted therapies and is developing additional programs in discovery. There are no FDA-approved drugs for mitochondrial diseases; clinical results have not been published but an expanded access protocol exists[1][3][5].

Therapeutic areas: NephrologyRare Diseases
Modalities: Small moleculeRNA therapy (tRNA-targeting)
Industry: Biotech

Drug pipeline

1 asset

R007

Preclinical

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on RiboNova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RiboNova.

Explore the full profile